Antipsychotic polypharmacy in schizophrenia: ‘Secret sauce or wild abandon?’

Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world"

Volumn , Issue , 2013, Pages 3-10

  Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938263704     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-5799-8_1     Document Type: Chapter

References (26)

1. Stahl SM (2012) Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand 125(5):349-351
2. Tamminga CA (2011) When is polypharmacy an advantage? Am J Psychiatry 168(7):663
3. Goff DC, Dixon L (2011) Antipsychotic polypharmacy: are two ever better than one? Am J Psychiatry 168(7):667-669
4. Stahl SM, Grady MM (2006) High-cost use of second-generation antipsychotics under California’s Medicaid program. Psychiatr Serv 57(1):127-129
5. Constantine RJ, Andel R, Tandon R (2010) Trends in adult antipsychotic polypharmacy: progress and challenges in Florida’s Medicaid program. Community Ment Health J 46(6):523-530
6. Baandrup L, Allerup P, Lublin H, Nordentoft M, Peacock L, Glenthoj B (2010) Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia outpatients. Acta Psychiatr Scand 122(5):367-374
7. Dussias P, Kalali AH, Citrome L (2010) Polypharmacy of schizophrenia. Psychiatry (Edgemont) 7(8):17-19
8. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized clinical trials. Schizophr Bull 35(2):443-457
9. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168:702-708
10. Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23(2):103-111
11. Lieberman JA, Stroup TS (2011) The NIMH-CATIE schizophrenia study: what did we learn? Am J Psychiatry 168(8):770-775
12. Bernardo M, Coma A, Ibanez C, Zara C, Bari JM, Serrano-Blanco A (2012) Antipsychotic polypharmacy in a regional health service: a population-based study. BMC Psychiatry 12(1):42
13. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, Johnson JL, Barr AM (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71(5):566-573
14. Friedman JI, Lindenmayer JP, Alcantara F, Bowler S, Parak M, White L, Iskander A, Parrella M, Adler DN, Tsopelas ND, Tsai WY, Novakovic V, Harvey PD, Davis KL, Kaushik S (2011) Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 36(6):1289-1295
15. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assuncao-Talbott S (2009) A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 70:1348-1357
16. Kantrowitz J, Javitt DC (2012) Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 25(2):96-102
17. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshansky V, Kishimoto T, Kane JM (2011) Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 131(1-3):58-62
18. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A (1997) Sulpride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 171:569-573
19. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD (2010) Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35(5):1053-1062
20. Buckley PF, Stahl SM (2007) Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 115(2):93-100
21. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115-1125
22. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC (2009) Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 29:165-169
23. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71:103-108
24. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P (2012) Polypharmacy with antip-sychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69(5):476-483
25. Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009) Psychiatric comorbidities and schizophrenia. Schizophr Bull 35(2):393-402
26. Insel TR (2010) Psychiatrists’ relationships with pharmaceutical companies: part of the problem or part of the solution? JAMA 303(12):1192-1193